This book analyzes in detail all aspects related to endocrine and metabolic late effects observed in patients treated for cancer, both in childhood and adulthood. The chapters focusing on the possible pathogenic mechanisms of late effects (i.e., premature aging and chronic inflammation) and on bone health in cancer survivors are particularly interesting and innovative. The volume also deals with hypothalamic-pituitary, thyroid and gonadal disorders, including infertility and how to prevent it. Finally, the relationship between metabolic alterations and cardiovascular diseases in cancer survivors is addressed. Thanks to advances in cancer treatment and supportive care, the five-year survival rate of cancer patients is constantly increasing. However, this undisputable success of medicine has a flip side: the late adverse effects of anticancer therapies. Pediatric oncologists were the first to cope with late complications of treatments, but today also adult oncologists and onco-hematologists recognize the relevance of this issue. Even though late effects observed in cancer survivors can affect any organ or system, endocrine and metabolic dysfunctions are the most frequently reported. Endocrine complications rarely influence life expectancy of cancer survivors, but they can significantly impact morbidity and quality of life. Among endocrine adverse effects, severe hypothalamic damage may be considered the most harmful in survivors, leading to morbid obesity, propensity to metabolic syndrome and cardiovascular disease. This book aims to disseminate the knowledge about endocrine and metabolic adverse effects of cancer therapies and about survivorship care. Since the number of cancer survivors is steadily growing in the general population, this publication is intended not only for endocrinologists but also for oncologists, onco-hematologists, internists, pediatric specialists in those areas and general practitioners, with the aim to better counsel and monitor cancer survivors.

The seventh edition of Brook's Clinical Pediatric Endocrinology has been compiled by an experienced editorial team and internationally renowned contributors; it presents basic science and clinical management of endocrine disorders for all involved in the care of children and adolescents. It provides treatments for a variety of hormonal diseases, including diabetes and hypoglycaemia, growth problems, thyroid disease and disorders of puberty, sexual differentiation, calcium metabolism, steroid metabolism and hypopituitarism.

Continuing advances in the management of childhood malignancies result in a rapidly growing number of childhood cancer survivors. However, many of them experience treatment-induced 'late effects' including a significant number of endocrine dysfunctions.In this book experts in the field of late effects of childhood cancer treatment offer clinical insight into pertinent issues such as the impact of cancer therapies on growth, puberty and hypothalamic and pituitary function, male and female fertility, obesity, and metabolic and bone problems.Multidisciplinary long-term follow-up of these patients is essential to monitor, treat and prevent morbidity. Therefore this volume is of great interest to pediatric endocrinologists and oncologists, adult and reproductive endocrinologists, primary care practitioners, nurses and nurse practitioners as well as others involved in planning and delivering the holistic care which this increasingly numerous and important group of patients requires.

This comprehensive guide describes the aftercare that is appropriate in young cancer patients and discusses in detail the risk and detection of treatment sequelae. It explains the impacts on body and mind of both the disease itself and the different risk-adapted cancer treatments currently in use. Clear guidance is provided on diagnosis and management of the principal treatment-related toxicities in different organs and organ systems and for a wide variety of tumor types. In addition, the role of genetic polymorphisms in the development of adverse therapy-related outcomes is explored, and advice offered on genetic counselling. As the number of long-term survivors of childhood cancer and of cancer in young adults continues to grow, so issues surrounding potential sequelae, second malignancies, and quality of life are becoming ever more important. All practitioners involved in the care of young cancer patients will find this book to be a helpful source of up-to-date information and assistance.

This unique handbook provides pediatric and adult endocrinologists and multidisciplinary clinical care providers a guide to transition from pediatric to adult care and an understanding of developmental and psychosocial issues of young adulthood and how they relate to healthcare and disease self-management. The handbook is divided into two parts. Part one describes transition interventions and novel strategies that can be integrated into routine care and gives practical considerations for transition processes from both the pediatric and adult perspectives, with applications across multiple endocrine conditions. Part two focuses on transition issues specific to common endocrine conditions – type 1 and type 2 diabetes, Turner syndrome, congenital adrenal hyperplasia, endocrine sequelae of childhood cancer, and transgender care – with condition-specific developmental and psychosocial issues, treatment and screening recommendations, healthcare process considerations, transition care guidelines, and key resources for more information. By highlighting medical, psychosocial, and healthcare delivery concerns relevant to transition to adult care, this book provides a practical, patient-centered overview of the essential information to supporting optimal adult care transition across a number of endocrine conditions. Timely and practical, Transitioning from Pediatric to Adult Care in Endocrinology: A Clinical Handbook is an excellent resource for pediatric and adult endocrinologists, behavioral healthcare providers, allied health professionals, primary care providers, and all clinical staff working with young people with endocrine conditions as they transition from children to adults.

The treatment of childhood cancer has become increasingly successful over the last forty years, and during the last two decades in particular, and the overall cure rate is now 60-70%. This, in turn, has introduced new issues for the clinician as the number of long-term survivors has increased. Some of the therapies that have contributed most to the